{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:18:26Z","timestamp":1780460306658,"version":"3.54.1"},"reference-count":139,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T00:00:00Z","timestamp":1585094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. By inhibiting enzymatic decomposition, DPP-4 inhibitors increase the half-life of incretins such as GLP-1 (Glucagon-like peptide-1) and GIP (Gastric inhibitors polypeptide) and prolong their action. Some studies present results suggesting the anti-sclerotic and vasculoprotective effects of vildagliptin reaching beyond glycemic control. Vildagliptin is able to limit inflammation by suppression of the NF-\u03baB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling pathway and proinflammatory agents such as TNF-\u03b1 (tumor necrosis factor \u03b1), IL-1\u03b2 (Interleukin-1\u03b2), and IL-8 (Interleukin 8). Moreover, vildagliptin regulates lipid metabolism; attenuates postprandial hypertriglyceridemia; and lowers serum triglycerides, apolipoprotein B, and blood total cholesterol levels. This DPP-4 inhibitor also reduces macrophage foam cell formation, which plays a key role in atheromatous plaque formation and stability. Vildagliptin reduces vascular stiffness via elevation of nitric oxide synthesis, improves vascular relaxation, and results in reduction in both systolic and diastolic blood pressure. Treatment with vildagliptin lowers the level of PAI-1 presenting possible antithrombotic effect. By affecting the endothelium, inflammation, and lipid metabolism, vildagliptin may affect the development of atherosclerosis at its various stages. The article presents a summary of the studies assessing vasculoprotective effects of vildagliptin with special emphasis on atherogenesis.<\/jats:p>","DOI":"10.3390\/ijms21072275","type":"journal-article","created":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T13:10:47Z","timestamp":1585141847000},"page":"2275","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis"],"prefix":"10.3390","volume":"21","author":[{"given":"Micha\u0142","family":"Wici\u0144ski","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, M. Curie 9, 85-090 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5732-9403","authenticated-orcid":false,"given":"Karol","family":"G\u00f3rski","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, M. Curie 9, 85-090 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2834-3414","authenticated-orcid":false,"given":"Eryk","family":"W\u00f3dkiewicz","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, M. Curie 9, 85-090 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4660-1330","authenticated-orcid":false,"given":"Maciej","family":"Walczak","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, M. Curie 9, 85-090 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-2903","authenticated-orcid":false,"given":"Magdalena","family":"Nowaczewska","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, and Laryngological Oncology, Faculty of Medicine, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, M. Curie 9, 85-090 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Malinowski","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, M. Curie 9, 85-090 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,25]]},"reference":[{"key":"ref_1","unstructured":"(2018, October 30). World Health Organization Diabetes. Available online: http:\/\/www.who.int."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"The Emerging Risk Factors Collaboration (2010). Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet, 375, 2215\u20132222.","DOI":"10.1016\/S0140-6736(10)60484-9"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.2165\/0003495-200868160-00009","article-title":"Vildagliptin: A Review of its Use in the Management of Type 2 Diabetes Mellitus","volume":"68","author":"Croxtall","year":"2008","journal-title":"Drugs"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.beem.2009.03.004","article-title":"Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)","volume":"23","author":"Thornberry","year":"2009","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/ajcn\/68.3.525","article-title":"Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men","volume":"68","author":"Gutniak","year":"1998","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1210\/jc.2012-2396","article-title":"Mechanism of Action of DPP-4 Inhibitors\u2014New Insights","volume":"97","author":"Vella","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4093\/dmj.2014.38.3.211","article-title":"The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes","volume":"38","author":"Choe","year":"2014","journal-title":"Diabetes Metab. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2165\/00003088-200746090-00006","article-title":"The Absolute Oral Bioavailability and??Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers","volume":"46","author":"He","year":"2007","journal-title":"Clin. Pharmacokinet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/11598080-000000000-00000","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin","volume":"51","author":"He","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1055\/s-2007-970422","article-title":"Vildagliptin in Drug-na\u00efve Patients with Type 2 Diabetes: A 24-Week, Double-blind, Randomized, Placebo-controlled, Multiple-dose Study","volume":"39","author":"Dejager","year":"2007","journal-title":"Horm Metab Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1124\/dmd.108.023010","article-title":"Absorption, Metabolism, and Excretion of [14 C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans","volume":"37","author":"He","year":"2009","journal-title":"Drug Metab Dispos."},{"key":"ref_12","first-page":"1215","article-title":"The Role of Vildagliptin in the Therapy of Type 2 Diabetic Patients with Renal Dysfunction","volume":"8","author":"Trevisan","year":"2017","journal-title":"Diabetes"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.metabol.2015.10.002","article-title":"Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate","volume":"65","author":"Lee","year":"2016","journal-title":"Metabolism"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12933-017-0503-0","article-title":"Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: A 12-month randomized controlled trial in patients with type 2 diabetes","volume":"16","author":"Spigoni","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.biopha.2018.09.148","article-title":"Vildagliptin protects endothelial cells against high glucose-induced damage","volume":"108","author":"Zhang","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/21691401.2019.1578783","article-title":"Vildagliptin inhibits high free fatty acid (FFA)-induced NLRP3 inflammasome activation in endothelial cells","volume":"47","author":"Qi","year":"2019","journal-title":"Artif. CellsNanomed. Biotechnol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/jcmm.13975","article-title":"Vildagliptin improves high glucose-induced endothelial mitochondrial dysfunction via inhibiting mitochondrial fission","volume":"23","author":"Liu","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s12012-018-9496-5","article-title":"Vildagliptin, an Anti-diabetic Drug of the DPP-4 Inhibitor, Induces Vasodilation via Kv Channel and SERCA Pump Activation in Aortic Smooth Muscle","volume":"19","author":"Seo","year":"2019","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/ATVBAHA.110.206425","article-title":"Glucagon-Like Peptide 1 Prevents Reactive Oxygen Species\u2013Induced Endothelial Cell Senescence Through the Activation of Protein Kinase A","volume":"30","author":"Oeseburg","year":"2010","journal-title":"Arter. Thromb Vasc Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.metabol.2011.11.011","article-title":"Effects of PKF275-055, a dipeptidyl peptidase\u20134 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E\u2013null mice","volume":"61","author":"Terasaki","year":"2012","journal-title":"Metabolism"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Terasaki, M., Nagashima, M., Nohtomi, K., Kohashi, K., Tomoyasu, M., Sinmura, K., Nogi, Y., Katayama, Y., Sato, K., and Itoh, F. (2013). Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin\u2019s Actions in Nondiabetic and Diabetic Apolipoprotein E-Null Mice. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0070933"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1517\/14728222.2016.1086338","article-title":"Potential effects of vildagliptin on biomarkers associated with prothrombosis in diabetes mellitus","volume":"19","author":"Khan","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.physbeh.2015.09.007","article-title":"Neuroprotective effect of selective DPP-4 inhibitor in experimental vascular dementia","volume":"152","author":"Jain","year":"2015","journal-title":"Physiol. Behav."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.jvs.2014.12.048","article-title":"Dipeptidyl peptidase 4 inhibitor reduces intimal hyperplasia in rabbit autologous jugular vein graft under poor distal runoff","volume":"63","author":"Koyama","year":"2016","journal-title":"J. Vasc. Surg."},{"key":"ref_25","first-page":"1","article-title":"A Possible Mechanism: Vildagliptin Prevents Aortic Dysfunction through Paraoxonase and Angiopoietin-Like 3","volume":"2018","author":"Zhang","year":"2018","journal-title":"BioMed Res. Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fphar.2019.00142","article-title":"Vildagliptin Reduces Stenosis of Injured Carotid Artery in Diabetic Mouse Through Inhibiting Vascular Smooth Muscle Cell Proliferation via ER Stress\/NF-\u03baB Pathway","volume":"10","author":"Ji","year":"2019","journal-title":"Front. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.2337\/dc10-2421","article-title":"Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes","volume":"34","author":"Netea","year":"2011","journal-title":"Dia Care"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3892\/etm.2014.2051","article-title":"Single administration of vildagliptin attenuates postprandial hypertriglyceridemia and endothelial dysfunction in normoglycemic individuals","volume":"9","author":"Noguchi","year":"2015","journal-title":"Exp. Ther. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.amjcard.2014.11.044","article-title":"Effect of Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin on Plasminogen Activator Inhibitor-1 in Patients with Diabetes Mellitus","volume":"115","author":"Tani","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/VHRM.S112148","article-title":"Blood pressure and fasting lipid changes after 24 weeks\u2019 treatment with vildagliptin: A pooled analysis in >2,000 previously drug-na\u00efve patients with type 2 diabetes mellitus","volume":"12","author":"Foley","year":"2016","journal-title":"VHRM"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13098-016-0144-6","article-title":"Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus","volume":"8","author":"Duvnjak","year":"2016","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/jdi.12572","article-title":"Vildagliptin reduces plasma stromal cell-derived factor-1\u03b1 in patients with type 2 diabetes compared with glimepiride","volume":"8","author":"Park","year":"2017","journal-title":"J. Diabetes Investig."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12933-017-0551-5","article-title":"The addition of vildagliptin to metformin prevents the elevation of interleukin 1\u00df in patients with type 2 diabetes and coronary artery disease: A prospective, randomized, open-label study","volume":"16","author":"Younis","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/1074248418817345","article-title":"The Role of Vildagliptin in Treating Hypertension Through Modulating Serum VEGF in Diabetic Hypertensive Patients","volume":"24","author":"Zaafar","year":"2019","journal-title":"J. Cardiovasc. Pharm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.7150\/ijbs.7502","article-title":"The Vascular Endothelium and Human Diseases","volume":"9","author":"Rajendran","year":"2013","journal-title":"Int. J. Biol. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1212\/WNL.0b013e3182695836","article-title":"Role of the vascular endothelium and plaque in acute ischemic stroke","volume":"79","author":"Madden","year":"2012","journal-title":"Neurology"},{"key":"ref_37","first-page":"1","article-title":"Harmful and Beneficial Role of ROS","volume":"2016","author":"Reed","year":"2016","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1161\/CIRCRESAHA.118.312708","article-title":"Mitochondrial ROS Drive Sudden Cardiac Death and Chronic Proteome Remodeling in Heart Failure","volume":"123","author":"Dey","year":"2018","journal-title":"Circ. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","article-title":"Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis","volume":"118","author":"Gimbrone","year":"2016","journal-title":"Circ. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"719","DOI":"10.4330\/wjc.v7.i11.719","article-title":"Vascular endothelial dysfunction and pharmacological treatment","volume":"7","author":"Su","year":"2015","journal-title":"World J. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3346\/jkms.2015.30.9.1213","article-title":"Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches","volume":"30","author":"Park","year":"2015","journal-title":"J. Korean Med. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1096\/fj.12-226225","article-title":"Dynamin-related protein 1 (Drp1)-mediated diastolic dysfunction in myocardial ischemia-reperfusion injury: therapeutic benefits of Drp1 inhibition to reduce mitochondrial fission","volume":"28","author":"Sharp","year":"2014","journal-title":"Faseb J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1475-2840-12-154","article-title":"Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner","volume":"12","author":"Hausenloy","year":"2013","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/1479164113516134","article-title":"Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemia\u2013reperfusion rat heart","volume":"11","author":"Chinda","year":"2014","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/1074248417729881","article-title":"Effect of Ischemic Postconditioning on Myocardial Function and Infarct Size Following Reperfusion Injury in Diabetic Rats Pretreated With Vildagliptin","volume":"23","author":"Bayrami","year":"2018","journal-title":"J. Cardiovasc. Pharm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jchf.2017.08.004","article-title":"Effects of Vildagliptin on Ventricular Function in Patients with Type 2 Diabetes Mellitus and Heart Failure","volume":"6","author":"McMurray","year":"2018","journal-title":"JACC Heart Fail."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1007\/s00018-016-2223-0","article-title":"Role of Nrf2\/HO-1 system in development, oxidative stress response and diseases: An evolutionarily conserved mechanism","volume":"73","author":"Loboda","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa043814","article-title":"Circulating Endothelial Progenitor Cells and Cardiovascular Outcomes","volume":"353","author":"Werner","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s10439-011-0486-z","article-title":"Upregulation of SDF-1 is Associated with Atherosclerosis Lesions Induced by LDL Concentration Polarization","volume":"40","author":"Wei","year":"2012","journal-title":"Ann. Biomed. Eng."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3389\/fimmu.2015.00477","article-title":"Dipeptidyl Peptidase-4 Regulation of SDF-1\/CXCR4 Axis: Implications for Cardiovascular Disease","volume":"6","author":"Zhong","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1084\/jem.20061609","article-title":"Stromal cell\u2013derived factor 1 promotes angiogenesis via a heme oxygenase 1\u2013dependent mechanism","volume":"204","author":"Deshane","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/01.RES.0000259043.42571.68","article-title":"Importance of CXC Chemokine Receptor 2 in the Homing of Human Peripheral Blood Endothelial Progenitor Cells to Sites of Arterial Injury","volume":"100","author":"Hristov","year":"2007","journal-title":"Circ. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.yexmp.2009.12.001","article-title":"CXCR4 positive bone mesenchymal stem cells migrate to human endothelial cell stimulated by ox-LDL via SDF-1\u03b1\/CXCR4 signaling axis","volume":"88","author":"Li","year":"2010","journal-title":"Exp. Mol. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/01.RES.86.2.131","article-title":"The Stromal Cell\u2013Derived Factor-1 Chemokine Is a Potent Platelet Agonist Highly Expressed in Atherosclerotic Plaques","volume":"86","author":"Sauty","year":"2000","journal-title":"Circ. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijcard.2015.07.044","article-title":"DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages","volume":"199","author":"Brenner","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1161\/ATVBAHA.114.303579","article-title":"Stromal Cell\u2013Derived Factor 1 as a Biomarker of Heart Failure and Mortality Risk","volume":"34","author":"Subramanian","year":"2014","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00125-016-3873-z","article-title":"Multiple benefits of targeting inflammation in the treatment of type 2 diabetes","volume":"59","author":"Donath","year":"2016","journal-title":"Diabetologia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1113\/JP270841","article-title":"Diabetes and ageing-induced vascular inflammation","volume":"594","author":"Assar","year":"2016","journal-title":"J. Physiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.jacc.2017.07.750","article-title":"Unraveling Vascular Inflammation","volume":"70","author":"Teague","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Gordon, S., and Pl\u00fcddemann, A. (2017). Tissue macrophages: heterogeneity and functions. BMC Biol., 15.","DOI":"10.1186\/s12915-017-0392-4"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Chen, L., Deng, H., Cui, H., Fang, J., Zuo, Z., Deng, J., Li, Y., Wang, X., and Zhao, L. (2018). Inflammatory responses and inflammation-associated diseases in organs. Oncotarget, 9.","DOI":"10.18632\/oncotarget.23208"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00041552-200303000-00009","article-title":"Vascular inflammation: A role in vascular disease in hypertension?","volume":"12","author":"Virdis","year":"2003","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0021-9150(01)00719-5","article-title":"High glucose induced nuclear factor kappa B mediated inhibition of endothelial cell migration","volume":"162","author":"Hamuro","year":"2002","journal-title":"Atherosclerosis"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/CIRCRESAHA.115.306361","article-title":"Vascular Smooth Muscle Cells in Atherosclerosis","volume":"118","author":"Bennett","year":"2016","journal-title":"Circ Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"eaah6037","DOI":"10.1126\/scisignal.aah6037","article-title":"Prostaglandin E 2 \u2013EP2\u2013NF-\u03baB signaling in macrophages as a potential therapeutic target for intracranial aneurysms","volume":"10","author":"Aoki","year":"2017","journal-title":"Sci. Signal."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2010.03.013","article-title":"Osteoprotegerin as a Predictor of Coronary Artery Disease and Cardiovascular Mortality and Morbidity","volume":"55","author":"Venuraju","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.bcp.2009.04.029","article-title":"Inflammatory cytokines in vascular dysfunction and vascular disease","volume":"78","author":"Sprague","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1128\/MCB.17.7.4015","article-title":"Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis","volume":"17","author":"Yoshida","year":"1997","journal-title":"Mol. Cell. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood.V94.6.1878","article-title":"Nuclear factor-kappaB-dependent induction of interleukin-8 gene expression by tumor necrosis factor alpha: evidence for an antioxidant sensitive activating pathway distinct from nuclear translocation","volume":"94","author":"Vlahopoulos","year":"1999","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.atherosclerosis.2014.03.020","article-title":"Pathology of human plaque vulnerability: Mechanisms and consequences of intraplaque haemorrhages","volume":"234","author":"Michel","year":"2014","journal-title":"Atherosclerosis"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0021-9150(99)00479-7","article-title":"The role of plaque rupture and thrombosis in coronary artery disease","volume":"149","author":"Zaman","year":"2000","journal-title":"Atherosclerosis"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3132\/dvdr.2005.001","article-title":"Pathobiology and cell interactions of platelets in diabetes","volume":"2","author":"Stratmann","year":"2005","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/978-3-319-48382-5_20","article-title":"Lipotoxicity-Related Hematological Disorders in Obesity","volume":"Volume 960","author":"Engin","year":"2017","journal-title":"Obesity and Lipotoxicity"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Wang, L., Chen, Y., Li, X., Zhang, Y., Gulbins, E., and Zhang, Y. (2016). Enhancement of endothelial permeability by free fatty acid through lysosomal cathepsin B-mediated Nlrp3 inflammasome activation. Oncotarget, 7.","DOI":"10.18632\/oncotarget.12302"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1007\/s11427-017-9285-1","article-title":"A potential strategy for treating atherosclerosis: improving endothelial function via AMP-activated protein kinase","volume":"61","author":"Gao","year":"2018","journal-title":"Sci. China Life Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.bbrc.2004.09.177","article-title":"AMPK inhibits fatty acid-induced increases in NF-\u03baB transactivation in cultured human umbilical vein endothelial cells","volume":"324","author":"Cacicedo","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin-1 in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello","year":"2011","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10557-014-6539-4","article-title":"DPP-4 Inhibitors Repress NLRP3 Inflammasome and Interleukin-1beta via GLP-1 Receptor in Macrophages Through Protein Kinase C Pathway","volume":"28","author":"Dai","year":"2014","journal-title":"Cardiovasc. Drugs"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Inflammation in Atherosclerosis","volume":"54","author":"Libby","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1139\/o03-085","article-title":"Lipids and atherosclerosis","volume":"82","author":"Choy","year":"2004","journal-title":"Biochem. Cell Biol."},{"key":"ref_82","first-page":"927","article-title":"Atherosclerosis: process, indicators, risk factors and new hopes","volume":"5","author":"Setorki","year":"2014","journal-title":"Int. J. Prev. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1142\/S1793984410000183","article-title":"Scavenger Receptor-mediated Targeting of Macrophage Foam Cells In Atherosclerotic Plaque Using Oligonucleotide-functionalized Nanoparticles","volume":"1","author":"Sharma","year":"2010","journal-title":"Nano Life"},{"key":"ref_84","first-page":"220","article-title":"Lipid Lowering Therapy for Atherosclerotic Cardiovascular Disease: It Is Not So Simple","volume":"104","author":"Vincent","year":"2018","journal-title":"Clin. Pharm."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.bbalip.2014.03.013","article-title":"Physiological regulation of lipoprotein lipase","volume":"1841","author":"Kersten","year":"2014","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"E1266","DOI":"10.1210\/jc.2012-1298","article-title":"Mutations in the ANGPTL3 Gene and Familial Combined Hypolipidemia: A Clinical and Biochemical Characterization","volume":"97","author":"Minicocci","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12944-016-0337-x","article-title":"Increased ANGPTL3, 4 and ANGPTL8\/betatrophin expression levels in obesity and T2D","volume":"15","author":"Cherian","year":"2016","journal-title":"Lipids Health Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1194\/jlr.M054890","article-title":"ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys","volume":"56","author":"Gusarova","year":"2015","journal-title":"J. Lipid Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0021-9150(03)00010-8","article-title":"Investigations of a common genetic variant in betaine\u2013homocysteine methyltransferase (BHMT) in coronary artery disease","volume":"167","author":"Weisberg","year":"2003","journal-title":"Atherosclerosis"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1172\/JCI1649","article-title":"Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase","volume":"101","author":"Aviram","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1161\/01.CIR.0000070954.00271.13","article-title":"Low Paraoxonase Activity Predicts Coronary Events in the Caerphilly Prospective Study","volume":"107","author":"Mackness","year":"2003","journal-title":"Circulation"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/01.CIR.0000023623.87083.4F","article-title":"Decreased Atherosclerotic Lesion Formation in Human Serum Paraoxonase Transgenic Mice","volume":"106","author":"Tward","year":"2002","journal-title":"Circulation"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"17527","DOI":"10.1074\/jbc.M910376199","article-title":"Combined Serum Paraoxonase Knockout\/Apolipoprotein E Knockout Mice Exhibit Increased Lipoprotein Oxidation and Atherosclerosis","volume":"275","author":"Shih","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3892\/mmr.2016.5233","article-title":"CLI-095 decreases atherosclerosis by modulating foam cell formation in apolipoprotein E-deficient mice","volume":"14","author":"Wang","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/nm.2538","article-title":"Atherosclerosis: current pathogenesis and therapeutic options","volume":"17","author":"Weber","year":"2011","journal-title":"Nat Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.mpdhp.2012.09.004","article-title":"Atherosclerosis: pathogenesis and pathology","volume":"18","author":"Wang","year":"2012","journal-title":"Diagn. Histopathol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cytogfr.2004.03.004","article-title":"PDGF and cardiovascular disease","volume":"15","author":"Raines","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/14779072.5.2.265","article-title":"Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability","volume":"5","author":"Johnson","year":"2007","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_100","unstructured":"Feingold, K.R., Anawalt, B., Boyce, A., Chrousos, G., Dungan, K., Grossman, A., Hershman, J.M., Kaltsas, G., Koch, C., and Kopp, P. (2000). The Role of Lipids and Lipoproteins in Atherosclerosis. Endotext, MDText.com, Inc."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1194\/jlr.M056689","article-title":"Macrophage SR-BI mediates efferocytosis via Src\/PI3K\/Rac1 signaling and reduces atherosclerotic lesion necrosis","volume":"56","author":"Tao","year":"2015","journal-title":"J. Lipid Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1089\/ars.2009.2469","article-title":"Macrophage Apoptosis in Atherosclerosis: Consequences on Plaque Progression and the Role of Endoplasmic Reticulum Stress","volume":"11","author":"Tabas","year":"2009","journal-title":"Antioxid. Redox Signal."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1111\/j.1538-7836.2005.01420.x","article-title":"PAI-1 and atherothrombosis","volume":"3","author":"Vaughan","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1111\/j.1755-5922.2010.00171.x","article-title":"REVIEW: Plasminogen Activator Inhibitor-1 (PAI-1): A Key Factor Linking Fibrinolysis and Age-Related Subclinical and Clinical Conditions: Plasminogen Activator Inhibitor-1 (PAI-1)","volume":"28","author":"Cesari","year":"2010","journal-title":"Cardiovasc. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/0002-8703(88)90440-1","article-title":"Reduction in plasminogen activator inhibitor-1 (PAI-1) with omega-3 polyunsaturated fatty acid (PUFA) intake","volume":"116","author":"Mehta","year":"1988","journal-title":"Am. Heart J."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1182\/blood.V96.13.4212","article-title":"Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery","volume":"96","author":"Eitzman","year":"2000","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12959-018-0166-4","article-title":"Association between plasminogen activator inhibitor-1 and cardiovascular events: A systematic review and meta-analysis","volume":"16","author":"Jung","year":"2018","journal-title":"Thromb. J."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/547809","article-title":"Essential Hypertension: An Approach to Its Etiology and Neurogenic Pathophysiology","volume":"2013","year":"2013","journal-title":"Int. J. Hypertens."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"18014","DOI":"10.1038\/nrdp.2018.14","article-title":"Hypertension","volume":"4","author":"Oparil","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ecl.2013.09.005","article-title":"Type 2 Diabetes Mellitus and Hypertension","volume":"43","author":"Lastra","year":"2014","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00467-013-2614-5","article-title":"Cardiovascular changes during chronic hypertensive states","volume":"29","author":"Drozdz","year":"2014","journal-title":"Pediatr. Nephrol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e019719","DOI":"10.1136\/bmjopen-2017-019719","article-title":"Combined antihypertensive and statin therapy for the prevention of cardiovascular events in patients with hypertension without complications: protocol for a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2018","journal-title":"BMJ Open"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1475-2840-13-19","article-title":"Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes","volume":"13","author":"Ott","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Zografou, I., Sampanis, C., Gkaliagkousi, E., Iliadis, F., Papageorgiou, A., Doukelis, P., Vogiatzis, K., and Douma, S. (2014). Effect of vildagliptin on hsCRP and arterial stiffness in patients with type 2 diabetes mellitus. HJ.","DOI":"10.14310\/horm.2002.1512"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/aps.2010.123","article-title":"Arterial stiffness: A brief review","volume":"31","author":"Shirwany","year":"2010","journal-title":"Acta Pharm. Sin."},{"key":"ref_117","first-page":"8","article-title":"Importance of arterial stiffness in predicting cardiovascular events","volume":"55","author":"Ecobici","year":"2017","journal-title":"Rom. J. Intern. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/801896","article-title":"Endothelium and Its Alterations in Cardiovascular Diseases: Life Style Intervention","volume":"2014","author":"Favero","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1152\/jappl.1997.83.6.1785","article-title":"Nitric oxide and vasodilation in human limbs","volume":"83","author":"Joyner","year":"1997","journal-title":"J. Appl. Physiol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.niox.2008.02.004","article-title":"A novel mechanism of vascular relaxation induced by sodium nitroprusside in the isolated rat aorta","volume":"18","author":"Bonaventura","year":"2008","journal-title":"Nitric Oxide"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1586\/erc.12.33","article-title":"Therapeutic strategies to combat neointimal hyperplasia in vascular grafts","volume":"10","author":"Collins","year":"2012","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease","volume":"71","author":"Pandey","year":"2018","journal-title":"Hypertension"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.12659\/MSM.894803","article-title":"Serum VEGF Predicts Worse Clinical Outcome of Patients with Coronary Heart Disease After Percutaneous Coronary Intervention Therapy","volume":"21","author":"Han","year":"2015","journal-title":"Med. Sci. Monit."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","article-title":"Diabetes and cardiovascular disease. The Framingham study","volume":"241","author":"Kannel","year":"1979","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"(1998). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352, 854\u2013865.","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/DMSO.S233538","article-title":"Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence","volume":"13","author":"Bonora","year":"2020","journal-title":"DMSO"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S2213-8587(19)30267-0","article-title":"GLP-1 receptor agonists and cardiovascular outcomes: An updated synthesis","volume":"7","author":"Standl","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.2337\/dc11-s202","article-title":"Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs","volume":"34","author":"Hirshberg","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes","volume":"369","author":"White","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1517\/14740338.2014.904284","article-title":"Gliptins \u2013 do they increase cardiovascular risk or benefit?","volume":"13","author":"Doggrell","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/dom.12548","article-title":"Cardiovascular and heart failure safety profile of vildagliptin: A meta-analysis of 17 000 patients","volume":"17","author":"McInnes","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.amjcard.2012.04.061","article-title":"Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus","volume":"110","author":"Patil","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/dom.12000","article-title":"Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: A meta-analysis of randomized clinical trials","volume":"15","author":"Monami","year":"2013","journal-title":"Diabetes Obes. Metab."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/7\/2275\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:11:34Z","timestamp":1760173894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/7\/2275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,25]]},"references-count":139,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["ijms21072275"],"URL":"https:\/\/doi.org\/10.3390\/ijms21072275","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,25]]}}}